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Abstract
We report a case of a patient with triple synchronous primary malignancies (breast, colon, kidney) which has not been previ-
ously reported in the literature. A 70-year-old woman was diagnosed with invasive ductal carcinoma of the left breast with
axillary lymph node metastasis. During the staging period, renal cell carcinoma on the left kidney and mucinous adenocar-
cinoma in the proximal colon were found. Since the breast tumour demonstrated favourable biology, aromatase inhibitor
therapy had been started and simultaneous right colectomy and left nephrectomy was performed. Six months after the first
diagnosis, left sector excision and axillary block dissection were performed. Adjuvant FEC chemotherapy was administered,
followed by radiotherapy. During the 16-month follow-up period disease recurrence was not detected.
INTRODUCTION
The occurrence of multiple primary malignant neoplasms is esti-
mated between 0.734% and 11.7% and shows increasing tendency
[1, 2]. According to the Warren and Gates diagnostic criteria, each
tumour should present a definite picture of malignancy, they
should be histologically distinct and none of these tumours
should be the metastasis of the others, diagnosed within 6
months could be defined as synchronous [3, 4]. We report a case
of a triple synchronous primary malignancies (breast, colon, kid-
ney) which has not been previously reported in the literature.
CASE REPORT
The present case is of a 70-year-old female patient with positive
family history of leukaemia, colon cancer and type 2 diabetes mel-
litus. In the annual breast cancer screening, the mammography
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revealed a 1.7 cm × 2.5 cmmass in the upper outer quadrant of her
left breast with axillary lymph node metastasis. Core biopsy con-
firmed invasive breast carcinoma (IBC) with low-grade ductal car-
cinoma in situ (DCIS), oestrogen and progesterone receptors were
both positive (ER 100%, Q-score 7–8, PR 70%, Q-score 3–4), Her2 was
negative (Score 0) and Ki67 labelling index was 5%. During the sta-
ging period, positron emission tomography-computed tomography
(PET-CT) scan was performed and it demonstrated an abnormal
FDG uptake in the upper part of the left kidney and in the right
colon too (Fig. 1). On colonoscopy, 7–8 polyps were detected and an
endophytic tumour in the ascending colon. Biopsy of the latter
mass revealed moderately differentiated mucinous adenocarcin-
oma. Computed tomography confirmed a 3.8 cm × 3.6 cm mass of
the left kidney and a 5 cm mass in the right colon extending until
the hepatic flexure. (Fig. 2) Percutaneous CT-guided fine needle
aspiration of the left kidney showed renal cell carcinoma. The case
was referred to the multidisciplinary oncological team.
Since the breast tumour showed favourable biology (Grade
1, invasive ductal carcinoma with hormone receptor positivity
and low Ki67 labelling index), our choice was to start her trat-
ment with a simultaneous right hemicolectomy and left neph-
rectomy. During this period, aromatase inhibitor therapy had
been administered for the breast cancer. Six months after the
first diagnosis of the breast cancer, left sector excision and axil-
lary block dissection were performed. After an uneventful
recovery, six cycle adjuvant 5-fluorouracil, epiadrimicin, cyclo-
phosphamid chemotherapy (FEC scheme) was administered
due to lymph node involvement, followed by radiotherapy
according to the international protocol. The follow-up period
consists of 16 months, the patient is disease free, no tumour
recurrence was noted. Postoperative histopathological evalu-
ation of the colon specimen demonstrated a 5 cm, Grade 2,
pT3N0 mucinous adenocarcinoma infiltrating the whole thick-
ness of the bowel wall. All 18 lymph nodes were devoid of
metastases. Venous invasion was present within the subserosa
of the bowel wall. Immunohistochemistry (IHC) revealed loss of
expression of MLH1 and PMS2 in tumour cells (but not within
stromal cells and lymphocytes), and weak nuclear reaction
with MSH6 and MSH2 was observed within tumour cells and
internal control cells (stromal cells and lymphocytes). The
localisation, the mucinous nature and the histological appear-
ance of the invasive cancer within the ascending colon all
pointed toward the involvement of the serrated pathway. For
clinical treatment purposes investigation of KRAS and BRAF was
advised to define whether this tumour could be resistant to 5FU
and anti-EGFR therapies (Fig. 3). By molecular analysis, the
Figure 1: Abnormal FDG uptake in the three localisation according to the sagittal and coronal view of the PET-CT. Axial view shows (A) the colon ascendens tumour,
(B) the left kidney tumour and (C) the left breast tumour. Coronal view shows (D) the left kidney tumour and the colon tumour and (E) the left breast tumour.
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tumour showed KRAS mutant and BRAF wild type. The renal
specimen comprised a 4.8 cm diameter, ISUP grade 1, pT3a renal
cell carcinoma with venous invasion (Fig. 5). The breast speci-
men revealed a 2.2 cm × 2.0 cm, Grade 2 invasive breast carcin-
oma (pT2N2a) with low-grade DCIS. Among the nine axillary
lymph nodes five demonstrated macrometastases (Fig. 4).
DISCUSSION
Cancer patients have a multiple cancer risk 10% higher in com-
parison to the general population [5]. Better understanding of
the molecular background of tumourgenesis may contribute to
establishing other treatment strategies in the future. Previously
found that microsatellite unstable cancers have a higher inci-
dence of synchronous and metachronous tumours [6]. In our
case colorectal cancer (CRC) showed microsatellite instability,
KRAS mutation and BRAF wild type characteristics. Since
within the invasive tumour MLH1 and PMS2 protein loss was
noticed exclusively within tumour cells, while internal control
cells (stromal cells and lymphocytes) had normal protein
expression by all 4 IHC, Lynch syndrome could be excluded. We
presumed a CpG island metilator phenotype to be the under-
lying cause. All lesions were locally advanced and following the
international guidelines adjuvant treatment of colon and breast
cancer were required. Combined adjuvant radio- and chemo-
therapy (FEC scheme) was given for the breast cancer. Our
standpoint was to treat both the colon and breast cancers—as
Figure 2: The right colon mass (A) and the left kidney mass (B) on the CT scan.
Figure 3: Mucinous adenocarcinoma of the colon. Panel with four columns and
two rows. Upper row shows HE staining, lower rows show microsatellite
instability with IHC. All of the same 40× magnification.
Figure 5: Clear cell carcinoma of the left kidney. Panel with two rows show HE
staining. Image in the centre 0.5× and on the lower-right corner 40×
magnification.
Figure 4: Adenocarcinoma of the left breast. Panel with four columns and three
rows. Upper rows show HE staining in the centre 0.5× and on the upper-right
corner 40× magnification. Lower rows show IHC all of the same 40× magnifica-
tion. Oestrogen receptor 100% positive (Q-score 7–8), progesterone receptor 70%
positive (Q-score 3–4), Her2 negative (Q-score 0), Ki67 index 5%.
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the FEC scheme contains 5FU—with no additional need to other
chemotherapeutic agents. Previous reports showed that patients
with deficient MMR colon cancers do not benefit from FU-based
adjuvant therapy and in stage II CRC it could even be harmful [7,
8]. We find that the given adjuvant therapy was relevant in our
case, which was based on the histological, molecular behaviour
and pathological stage of each tumour. The therapeutic choice
was made possible by the widespread preoperative examination.
Although PET-CT scan is not part of the routine preoperative
examination, in our case it was eligible according to the
National Health Insurance Fund of Hungary. The PET-CT scan
provided a complex view on all tumours and the possible metas-
tases which facilitated the appropriate therapeutical decision
making. Additionally, a recent study concluded that PET-CT can
help in accurate staging and might result in a more specified
prognostication compared to the conventional CT imaging [9].
The delay of the surgical treatment of breast cancer was possible
due to its favourable biological behaviour and therefore the sur-
gical treatment of kidney and colon tumours could be carried
out first. During this period, aromatase inhibitors could be
started for the breast cancer based on its receptor positivity. In
the aforementioned case, we needed to decide the best strategy
of treatment based on the biological behaviour of each tumour.
The widespread preoperative examination and the collaboration
of the interdisciplinary team played a key role in adopting the
potentially most effective and personalised treatment.
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